MCID: NSL004
MIFTS: 18

Nasal Cavity Lymphoma malady

Categories: Cancer diseases, Immune diseases, Respiratory diseases

Aliases & Classifications for Nasal Cavity Lymphoma

Aliases & Descriptions for Nasal Cavity Lymphoma:

Name: Nasal Cavity Lymphoma 12 14 69
Lymphoma of the Nasal Cavity 12
Lymphoma of Nasal Cavity 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10813
NCIt 47 C6074
UMLS 69 C1334921

Summaries for Nasal Cavity Lymphoma

MalaCards based summary : Nasal Cavity Lymphoma, also known as lymphoma of the nasal cavity, is related to lymphoma and malignant essential hypertension. An important gene associated with Nasal Cavity Lymphoma is ANKRD11 (Ankyrin Repeat Domain 11). The drugs Fentanyl and Apixaban have been mentioned in the context of this disorder. Related phenotype is Decreased shRNA abundance.

Related Diseases for Nasal Cavity Lymphoma

Diseases related to Nasal Cavity Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 lymphoma 10.0
2 malignant essential hypertension 9.8 ANKRD11 B2M
3 b-cell lymphomas 9.7
4 diffuse large b-cell lymphoma 9.7
5 sinusitis 9.7
6 dacryoadenitis 9.7

Graphical network of the top 20 diseases related to Nasal Cavity Lymphoma:



Diseases related to Nasal Cavity Lymphoma

Symptoms & Phenotypes for Nasal Cavity Lymphoma

GenomeRNAi Phenotypes related to Nasal Cavity Lymphoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance GR00251-A-1 9.23 ANKRD11 B2M
2 Decreased shRNA abundance GR00251-A-2 9.23 ANKRD11 B2M

Drugs & Therapeutics for Nasal Cavity Lymphoma

Drugs for Nasal Cavity Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Apixaban Approved Phase 3 503612-47-3 10182969
3
Asparaginase Approved Phase 3 9015-68-3
4
Pegaspargase Approved, Investigational Phase 3 130167-69-0
5 Liver Extracts Phase 3,Phase 2,Phase 1
6 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
7
protease inhibitors Phase 3,Phase 2,Phase 1
8 Adjuvants, Anesthesia Phase 3
9 Analgesics Phase 3
10 Analgesics, Opioid Phase 3
11 Anesthetics Phase 3
12 Anesthetics, General Phase 3
13 Anesthetics, Intravenous Phase 3
14 Central Nervous System Depressants Phase 3
15 Narcotics Phase 3
16 pancreatic polypeptide Phase 3
17 Peripheral Nervous System Agents Phase 3,Phase 1
18 Anticoagulants Phase 3
19 Antithrombin III Phase 3
20 Antithrombins Phase 3
21 Factor Xa Inhibitors Phase 3
22 Pharmaceutical Solutions Phase 3
23 Serine Proteinase Inhibitors Phase 3
24 Cola Nutraceutical Phase 3,Phase 2,Phase 1
25 serine Nutraceutical Phase 3
26
Indinavir Approved Phase 2 150378-17-9 5362440
27
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
28
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
29
Carmustine Approved Phase 2 154-93-8 2578
30
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
31
Etoposide Approved Phase 2 33419-42-0 36462
32
Lenograstim Approved Phase 2 135968-09-1
33
Thiotepa Approved Phase 2 52-24-4 5453
34
Cyclosporine Approved, Investigational, Vet_approved Phase 2 79217-60-0, 59865-13-3 5284373 6435893
35
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
36
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
37
nivolumab Approved Phase 2 946414-94-4
38 Anti-HIV Agents Phase 2
39 Anti-Infective Agents Phase 2,Phase 1
40 Anti-Retroviral Agents Phase 2
41 Antiviral Agents Phase 2,Phase 1
42 Cytochrome P-450 CYP3A Inhibitors Phase 2
43 Cytochrome P-450 Enzyme Inhibitors Phase 2
44 Alkylating Agents Phase 2
45 Antineoplastic Agents, Alkylating Phase 2
46 Antirheumatic Agents Phase 2
47 Immunosuppressive Agents Phase 2,Phase 1
48 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
49 Etoposide phosphate Phase 2
50 Topoisomerase Inhibitors Phase 2,Phase 1

Interventional clinical trials:

(show all 21)
id Name Status NCT ID Phase
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
2 A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Pegylated (PEG) L-Asparaginase Recruiting NCT02369653 Phase 3
3 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
4 Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer Completed NCT00007982 Phase 2
5 Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies Completed NCT00079391 Phase 2
6 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
7 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1
8 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1
9 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1
10 Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer Completed NCT00036790 Phase 1
11 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1
12 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1
13 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1
14 Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer Completed NCT00060372 Phase 1
15 Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases Active, not recruiting NCT01447056 Phase 1
16 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1
17 Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin Terminated NCT00023790 Phase 1
18 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733
19 Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer Completed NCT00002520
20 Questionnaire in Screening Older Patients With Cancer Completed NCT00963911
21 Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial Completed NCT00904514

Search NIH Clinical Center for Nasal Cavity Lymphoma

Genetic Tests for Nasal Cavity Lymphoma

Anatomical Context for Nasal Cavity Lymphoma

Publications for Nasal Cavity Lymphoma

Variations for Nasal Cavity Lymphoma

Expression for Nasal Cavity Lymphoma

Search GEO for disease gene expression data for Nasal Cavity Lymphoma.

Pathways for Nasal Cavity Lymphoma

GO Terms for Nasal Cavity Lymphoma

Sources for Nasal Cavity Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....